MedPath

injection of anesthetic medicine in fraction versus in single bolus for lower limb and lower abdominal surgeries

Not yet recruiting
Conditions
patients posted for lower abdominal and lower limb surgeries
Registration Number
CTRI/2018/04/013184
Lead Sponsor
Shilpa Bhimasen Joshi
Brief Summary

Afterethical committee approval and informed consent, patients will be recruited forthe study. Preoperative evaluation is doneand  the subjects will be randomized via computergenerated table and  allocated to one ofthe groups.  Group B:  3.6 ml of 0.5%  hyperbaric Bupivacaine,Group F : 3.6 ml of  0.5%  hyperbaric Bupivacaine in fractionatedapproach.   Demographic details (Age,sex, weight, ASA status, height) will be noted.

 Asa standard practice, pre-operatively patients will be kept fasting for 6 hours.They will be routinely premedicated with Tab. Alprazolam 0.5 mg and Tab.Pantoprazole 40 mg on the night prior to surgery and on the morning ofsurgery.

 Intraoperativelypatients will be monitored by electrocardiography, non-invasive blood pressureand pulse oximetry.  In group B - Spinalanesthesia will be given with 3.6cc of 0.5% heavy Bupivacaine at L3-4interspace via 25 G spinal needle, with subject  in the sitting position . In group F - Spinalanesthesia  of 3.6cc of 0.5% heavyBupivacaine at L3-4 interspace via 25 G spinal needle will be given in afractionated approach where 2.4cc(2/3rd) will be given first andthen the remaining 1.2ml (1/3rd) will be given after 120sec.Thesubject will made to lie supinesoon  after the injection. At 5 mins after theinjection, level of block –sensory by pinprick and motor by bromage scale willbe checked. This  will be considered asonset of sensory and motor block.  At20min, the peak level of sensory and motor block willalso  be noted.

 Theduration of spinal anesthesia is considered as two segment regression from  the level of sensory block achieved  at 20min(peak) of sensory block . At the endof surgery, both the sensory level and motor block will be rechecked. Vitalssuch as   Heart rate (HR),   Systolic blood pressure (SBP), Diastolicblood pressure (DBP), Mean arterial blood pressure (MAP), saturation (SpO2)will be measured at every  5 mins for 1sthourand then 10min till the end of surgery.

 Anyside effects of the spinal anesthesia  such as: Bradycardia (HR < 20% ofbaseline), Hypotension (BP < 25% of baseline), Respiratory depression,Sedation, Pruritis and Nausea/ Vomiting will be noted and treatedappropriately. Bradycardia will be treated with Injection Atropine 20mcg/kg IVand Hypotension by IV fluids/ injection Mephentermine 3 mg  IV boluses.

 Thedata will be collected in the study proforma and analyzed for statisticalsignificance with the statistician.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

ASA I-II patients undergoing lower abdominal or lower limb surgery under spinal anesthesia.

Exclusion Criteria

a)Patient refusal b)Allergy to Bupivacaine c)Body mass index (BMI) > 35 d)Intra-operative conversion to general anesthesia (GA) / inadequate or failed spinal block e)Pregnant and lactating mothers f)Known bleeding diathesis or with any coagulation abnormalities.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the onset, peak and duration of sensory and motor block in fractionated and single bolus dose of spinal anesthesia with 0.5% heavy bupivacaine for lower abdominal and lower limb surgeries.5,10,15,20,25,30,60,90,120,150,180,210 minutes after spinal injection
Secondary Outcome Measures
NameTimeMethod
1)To compare the intraoperative hemodynamics heart rate, saturation,systolic blood pressure, diastolic blood pressure, mean blood pressure and any side effects

Trial Locations

Locations (1)

St Johns Medical College

🇮🇳

Bangalore, KARNATAKA, India

St Johns Medical College
🇮🇳Bangalore, KARNATAKA, India
Shilpa Bhimasen Joshi
Principal investigator
9901405136
drshilpa.josh@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.